Navigation Links
New Data on Vimpat® (lacosamide) C-V to Be Presented at the 65th Annual Meeting of the American Epilepsy Society
Date:11/30/2011

mation/human/000863/WC500050338.pdf (Accessed 18 October, 2011).

Further Information
Andrea Levin
Senior Manager, Communications & PR, CNS, UCB, Inc.
T 770.970.8352
Andrea.levin@ucb.com

Dana Gulick   
Cooney/Waters Group
T 212.886.2227 / M 917.216.6268
DGulick@cooneywaters.com

About UCB
UCB, Brussels, Belgium (www.ucb-usa.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

Forward Looking Statement
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.

[1] http://epilepsyfoundation.org/aboutepilepsy/

[2] http://epilepsyfoundation.org/aboutepilepsy/treatment/index.cfm

 


'/>"/>
SOURCE UCB, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Analysis Shows Potential Cost Savings of Adding Antiepileptic Drug Vimpat® C-V
2. Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium
3. XEOMIN® (incobotulinumtoxinA) Data to be Presented at the 72nd Annual Assembly of the American Academy of Physical Medicine and Rehabilitation
4. New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI
5. Abbott Statement on the Results of the AIM-HIGH Study Presented at AHA 2011
6. Positive Results from Phase 2 Trial of Mesoblasts Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting
7. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting
9. LX2931 Phase 2 Data to be Presented at the American College of Rheumatology Conference
10. Discovery Labs Releases New AFECTAIR™ Performance Data Presented at the American Association for Respiratory Care Annual Meeting
11. Caliper CEO Kevin Hrusovsky Presented Vision for Revolutionizing Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 Research and Markets has ... Aseptic Packaging Industry Report 2014" report to their ... The Global and Chinese Aseptic Packaging Industry Report ... state of the global Aseptic Packaging industry with a ... a basic overview of the industry including definitions, classifications, ...
(Date:7/30/2014)... N.J. , July 30, 2014  InnoPharma, Inc. ... Injection, 10mg/vial (the generic equivalent of Zyprexa® injection), in ... agitation and disturbed behaviors in patients with schizophrenia or ... this generic injectable drug, InnoPharma has entered into an ... Sandoz Canada will make, use, sell, market and ...
(Date:7/30/2014)... and KISSING, Germany , July 30, ... a single use and computer-assisted ("robotic") colonoscopy system, today ... a worldwide recognized medical device executive, as a new ... Shamir is a highly respected global visionary in the ... served as President and Chief Executive Officer at Given ...
Breaking Medicine Technology:Global and Chinese Aseptic Packaging Industry Report 2014 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3
... Isis Pharmaceuticals,Inc. (Nasdaq: ISIS ) announced ... from a randomized Phase 2 clinical trial of,OGX-011 ... arm"),compared to docetaxel and prednisone alone ("the control ... cancer. The current 10.6,month median overall survival ...
... DIEGO, Dec. 3 Vical Incorporated,(Nasdaq: VICL ... with EIP,Eczacibasi Ilac Pazarlama A.S. (EIP) for sales and ... and the Turkish,Republic of Northern Cyprus. EIP has agreed ... to pay Vical upfront and milestone payments,plus a specified ...
Cached Medicine Technology:Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5
(Date:7/30/2014)... (July 30, 2014) The phrase "we caught it early" ... in the midst of a cancer diagnosis. Combating cancer ... to a certain part of the body, gives patients ... breast, skin, colon, prostate and other forms of cancer ... health care providers recommend cancer screenings as a precautionary ...
(Date:7/30/2014)... Orange, NJ. July 30, 2014. A new network of ... NIH Stroke Trials Network (NIH StrokeNet) is working ... the U.S. Despite advances of the last two ... year, stroke causes death or disability for 795,000 Americans. ... aging of the population. , To accelerate the ...
(Date:7/30/2014)... 30, 2014 The Technology Association of ... of TAG (B&TA), today issued its final call for ... , Interested companies have until August 29th 2014 to ... will be selected by the Excalibur Judging Committee. Companies ... with the judges for interviewing process. , The ...
(Date:7/30/2014)... July 30, 2014 Over 630 doctors ... Surgical Technique®, the revolutionary minimally invasive treatment for gum ... by many of his peers to be the “father ... at a recent Chao Pinhole Surgical Technique® training course ... Shanelec is the recipient of the American Academy of ...
(Date:7/30/2014)... July 30, 2014 As the controversy ... in gynecological surgeries continues to grow, Bernstein Liebhard LLP ... those calling for a ban on uterine morcellation. According ... was diagnosed with leiomyosarcoma following a hysterectomy that involved ... of her diagnosis, the aggressive cancer had progressed to ...
Breaking Medicine News(10 mins):Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3Health News:Periodontist Dr. Dennis Shanelec Comments On The Chao Pinhole Surgical Technique® Training Course 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 2Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 3Health News:Power Morcellator Controversy Grows, as Bernstein Liebhard LLP Notes Another Call to Ban Uterine Morcellation 4
... a greater risk of suffering from overweight and obesity. This ... children examined on starting school. Elisabeth Weber and her coauthors ... rzteblatt International ( Dtsch Arztbl Int 2008; 105 ... weight, and height of the children, but also their mother ...
... they behave like engineering parts is the focus of research ... 8 million grant from the Engineering and Physical Sciences Research ... synthetic biology. This is a field in which engineers work ... These parts could be used to build biological devices that ...
... want it must give up aggressive treatments, researchers say ... with life-threatening illnesses would seek hospice care if Medicare ... give up aggressive treatment of their ailments, a new ... but the issue was one of money, not race, ...
... is now open. The auction will run from December 18, ... Nick Foundation, Inc, a charity dedicated to male breast cancer awareness ... timeshares to donated items guaranteed to delight and surprise. Tell your ... ...
... Ride Home Program on New Year,s Eve , ... Terre Haute, Ind. (PRWEB) December 22, ... Yellow Cab of Terre Haute to provide free transportation to those who can,t ... Eve. The Safe and Sober Free Cab Ride Home program will be available ...
... -- A new study finds that hospice servicescare that ... aides, social workers and counselorshave restrictions that reduce usage ... Americans. The research, published in the February 1, 2009 ... the American Cancer Society, indicates that the eligibility criteria ...
Cached Medicine News:Health News:New center launched today to spearhead UK research in synthetic biology 2Health News:New center launched today to spearhead UK research in synthetic biology 3Health News:Rules Change Could Increase Hospice Use 2Health News:Holiday Online Auction - Dedicated to Awareness of Male Breast Cancer - Hosted by John W. Nick Foundation, Inc. at MaleBreastCancer.org 2Health News:Fleschner, Stark, Tanoos & Newlin to Offer Free Terre Haute Cab Rides on New Year's Eve 2Health News:Fleschner, Stark, Tanoos & Newlin to Offer Free Terre Haute Cab Rides on New Year's Eve 3Health News:Eligibility criteria contribute to racial disparities in hospice use 2
... interventional cardiology, accurate lesion assessment ... in determining the appropriate stent ... Cardiac 3-D (IC3D), a highly ... clinicians are now able to ...
... versatile solution designed to optimize the workflow ... to diagnosis and therapy, for both diagnostic ... your cath lab becomes an integral part ... free to concentrate on what really matters: ...
... FC is a floor-mounted, single ... system architecture for vascular and ... flexible and ergonomic system architecture ... the system configuration to focus ...
The ACUSON Sequoia C512 system elevates imaging and Doppler performance through new, high-density acoustic sampling, precise control of the transmitted acoustic waveform, and new transducer technolog...
Medicine Products: